Background: Diabetes is a complex progressive disease characterized by chronic
| INTRODUCTION
The incidence of diabetes mellitus is increasing throughout the world, and numbers are expected to reach 592 million by the year 2035, mainly because of the increase in obesity. 1 Despite the differences in aetiology, clinical presentation, and disease prevalence, secondary complications, such as endothelial dysfunction, occur in both types 1 and 2 diabetes. Diabetes complications are largely resistant to treatments posing a huge economic burden to the health system and society. Endothelial dysfunction renders diabetics vulnerable to limb infections and end-organ damage such as nephropathy, neuropathy, and retinopathy. 2 As yet, there are no biomarker predictors to indicate endothelial dysfunction in diabetes.
In recent decades, strategies for managing vascular complications associated with diabetes have moved away from a "glucocentric" approach to address additional risk factors that contribute to the development and progression of atherosclerosis. The presence of an atherogenic lipid profile is common in diabetic patients and is characterized by elevated plasma triglyceride (TG) levels, low levels of highdensity lipoprotein (HDL) cholesterol, and a preponderance of small dense low-density lipoprotein (LDL) particles. Oxidized LDL (Ox-LDL)
is a key component in the genesis of the atherosclerotic lesion and is cytotoxic to various cell types including endothelial cells (ECs) and therefore is suggested to contribute to endothelial dysfunction. Abbreviations: AGEs, advanced glycation end products; STZ, streptozotocin; Ox-LDL, oxidative low-density lipoprotein; HDL, high-density lipoprotein; TGs, triglycerides; eNOS, endothelial nitric oxide synthase; CAV-1, caveolin-1; CC, carbachol; ECs, endothelial cells; NA, noradrenaline
Caveolae form highly organized microdomains in the ECs plasma membrane through providing docking sites for numerous signalling molecules, such as endothelial nitric oxide (NO) synthase (eNOS). 4 Caveolin-1 (CAV-1) is a principal protein and marker found in the endothelial caveolae 5 and is co-localized with eNOS in cultured bovine aortic ECs. 6 Furthermore, both CAV-1 and eNOS are significantly downregulated in diabetic kidneys 7 linked to decreased renal eNOSderived NO and diabetic cavernosal tissues decreased NO mediated relaxation leading to erectile dysfunction. 8 Disruption of endothelial caveolae leading to eNOS uncoupling and diminished flow-mediated dilation in coronary arterioles of diabetic patients has also been observed. 9 We have previously shown that abnormal vascular responsiveness in STZ-diabetic rats is attributed in part to the overproduction of reactive oxygen species. 10 Here, we aim to investigate the alteration in non-HDL, HDL, Ox-LDL, cholesterol, and TG serum concentrations and whether it is associated with changes in the expression of eNOS and CAV-1 proteins in EC together with aortic vascular dysfunction using the STZ-diabetic rat model.
| MATERIALS AND METHODS

| Materials and reagents
Streptozotocin (STZ, S-0130) was purchased from Sigma-Aldrich (UK).
Oxidized LDL sandwich ELISA (SEA527Ra) was from Cloud clone corp.
Low-density lipoprotein, HDL, cholesterol, and TG Randox (Rx) Monza kits (CH 202 and CH 203) were from Randox (www.randox.com). All culture reagents were from Fischer Scientific. The rabbit primary antibody for eNOS (PA3-031A) and CAV-1 (PA5-17447) was obtained from Thermo Fisher Scientific. The fluorescence goat secondary antirabbit antibody (FI-1000) was obtained from Vector laboratories.
All other chemicals were of analytical grade and were obtained from local companies. 
| Induction of diabetes
| Statistical analysis
All data are expressed as mean ± standard error of the mean. "n" refers to independent values, not replicates. Data subjected to statistical analysis have n of at least 4 per group. Data were analysed by either an unpaired t test or repeated measures or 2-way ANOVA followed by Bonferroni's post-hoc test, using GraphPad prism version 5.00. Differences were considered to be statistically significant when P < .05. P values lower than .05 are expressed as P < .01 or .001. Carbachol and was sustained throughout the study. Blood glucose was significantly elevated in STZ-diabetic rats (>4-fold) as early as day 7 compared with age-matched control rats (STZ-diabetic: 29 ± 0.9 mmol/L; control: 7.2 ± 0.2 mmol/L P < .001, Figure 1 ). Animal health was closely monitored daily, and it was noted that, although the STZ-diabetic animals failed to increase body weight, they did manage to maintain their starting weights (data not shown). All STZ diabetic animals showed typical symptoms of the disease such as polydipsia, polyuria, glycosuria, and hyperglycaemia (data not shown).
Compared with the control group, the levels of Ox-LDL and TGs were significantly increased in serum from STZ-diabetic rats (Figure 2 B and C). Serum non-HDL cholesterol in STZ-diabetic rats just failed to reach significance compared with control rats (P = .1, Figure 2A ), while TGs increased 3-fold ( Figure 2C) . A small but significant increase in total serum cholesterol was noted ( Figure 2E ), although serum HDL cholesterol remained unchanged in STZ-diabetic rats compared with controls ( Figure 2D ).
| Effect of STZ on carbachol-induced aortic vascular relaxation
The increase in Ox-LDL and TGs was accompanied by a significant STZ-diabetic aortic dysfunction as shown in Figure 3 . Aortic rings precontracted with 300-nM noradrenaline from STZ-diabetic rats showed a significant increase in vasoconstriction (0.37 ± 0.02 g, P < .05) compared with control rat aorta (0.30 ± 0.02 g) and a significant decrease in vascular relaxant response to CC (EC 50 = 0.8 ± 0.4 μM and E max = 29.6 ± 9.3%, P ˂ .001) compared with control rat aorta (EC 50 = 0.6 μM ± 0.2 μM and E max = 77.2 ± 2.5%). In separate experiments, control rat aortic rings preincubated with L-NAME (100 μM) for 30 minutes (E max = 11.3 ± 1.6%), and when endothelium was denuded (E max = 12.5 ± 4.7%), both showed a significant decrease (P ˂ .001) in vascular relaxation in response to CC when compared with control rat aorta (E max = 77.2 ± 2.5%, data not shown). These data provide a causal link between altered NO synthase and altered aortic vasorelaxation.
| Effect of STZ on aortic endothelial cell eNOS staining
To investigate whether the reduced aortic vasorelaxation response in STZ-diabetic rats might be due to dysfunction in NO generation by ECs, we investigated primary cultures of ECs from control and STZdiabetic rat aorta. The LSCM images of EC cells stained with eNOS antibody showed distinct distribution of eNOS around the nucleus FIGURE 1 Effect of streptozotocin (STZ) diabetes on blood glucose (mmol/L) at day 0, day 7, and day of death (second week post injection). Significantly different from control group is denoted by ***P < .001, $$$P < .001 versus day 0 using 2-way ANOVA followed by Bonferroni's post-hoc test. Data are presented as mean ± SEM (control n = 16, STZ n = 24) Significance is denoted by *P < .05, **P < .01 different from control group, using unpaired 2-tailed t test. Serum non-HDL (A) STZ versus control was close to significance at P = .1 and at the edges of the plasma membrane (indicated by yellow arrows in Figure 4A ). Control ECs showed significantly higher eNOS expression compared with STZ-diabetic ECs (control N = 5 average expression 100.0 ± 4.3% vs STZ-diabetic N = 6, 62.1 ± 5.8%) ( Figure 4C ).
| Effect of STZ on aortic endothelial cell CAV-1 staining
Caveolae are 50-to 100-nm diameter lipid raft invaginations in the EC membrane. Caveolae form approximately 95% of the ECs surface invaginations and function as a signalling platform that facilitates interactions of signalling molecules. 12 Among the signalling molecules docked in the caveolae is eNOS. 6 Caveolin-1 is a major protein component of the endothelial caveolae. Previous studies have shown that eNOS and CAV-1 are co-localized in rat kidneys and cultured bovine aortic ECs. 6,7 Accordingly, we hypothesized that the levels of eNOS and CAV-1 proteins are altered in STZ-diabetic rat aortic ECs. Immunocytochemistry studies were conducted, which showed significant CAV-1 downregulation and disruption in STZ-diabetic aortic ECs ( Figure 5A and B). Total CAV-1 expression showed a significant reduction in STZ-diabetic rat aortic ECs compared with control rat aortic ECs (control, N = 5 average expression 100.0 ± 3.0% vs STZ N = 4, 73.8 ± 4.3%) ( Figure 5C ).
| DISCUSSION
In this study, STZ-diabetic rats developed symptoms of diabetes such as hyperglycaemia by day 7 which was sustained over 24 days (Figure 1) , consistent with others. 13 Furthermore, we have previously shown that endothelial dysfunction is evident as early as 8 days
Endothelial nitric oxide synthase (eNOS) expression in primary endothelial cells (ECs) from control and diabetic rat aorta under laser scanning confocal microscopy. A and B, Control and streptozotocin (STZ) diabetic aortic ECs, respectively. Endothelial cells were probed with DAPI to label the nucleus in blue and marked with acetylate oxidized low-density lipoprotein giving the cells the red colour (a1 and b1). Anti-eNOS primary antibody probed with secondary fluorescence antibody showed distinct distribution around the nucleus and at the edge of plasma membrane in control naïve aortic ECs as pointed by the arrows (a2). Streptozotocin-diabetic ECs showed disrupted eNOS distribution with less fluorescence light emission (b2). Images were combined to merge endothelial marker (red), nucleus marker (blue), and eNOS fluorescence antibody (green) (a3 and b3). C, Quantitative analysis of eNOS immunoreactivity. Data are mean ± SEM (N = 5-6) of total eNOS expression (% of control) in rat aortic ECs. Streptozotocin diabetic ECs showed a significant reduction in eNOS expression compared with control aortic ECs. Significance is represented as ***P ˂ .001 versus control when analysed through 2 tailed unpaired student t test following STZ injection, and hence, lipid markers and endothelial dysfunction were measured during the second week post-STZ injection in this study.
14 Herein, we demonstrated a state of hyperlipidaemia (elevation of serum TGs, cholesterol, and Ox-LDL) in this type 1 model of diabetes.
Compared with the control group, the levels of Ox-LDL and TGs were significantly increased in serum from STZ-diabetic rats (Figure 2 ). However, serum non-HDL cholesterol (which include LDL, very LDL, and ILDL) levels in STZ rats, though elevated, did not show a significant difference when compared with control levels (P = 1.0). Triglycerides increased 3-fold in serum in line with the 4-fold increase in blood glucose ( Figure 2) . A small but significant increase in total cholesterol was noted, although HDL levels remained unchanged, in STZ-diabetic rats compared with controls ( Figure 2 ). This hyperlipidaemia is consistent with previous findings in noninsulin-treated type 1 diabetic patients 15 and type 1 diabetes models (with no insulin replacement therapy). 16, 17 The elevated serum TGs and Ox-LDL in STZ-diabetic rats may be attributed to increased production and decreased clearance of TG-rich lipoproteins. In adipose tissues, insulin suppresses lipolysis by inhibiting the activity of hormone sensitive lipase, which catalyses the mobilization of free fatty acids from stored TGs. 18 The STZ-mediated destruction of the pancreatic β-cells results in an insulinopaenic state in STZ-diabetic rats, and hence, the lack of insulin will result in an increased lipolysis of TG-rich lipoproteins (LDL and TGs), and Significance is represented as *P ˂ .05 versus control when analysed through 2 tailed unpaired student t test furthermore, given carbohydrates can no longer be utilized efficiently as an energy source, this leads to a greater reliance on energy from fat and protein to meet the energy demands of the animal. 19 Similar to previous findings in type 2 diabetic patients, we observed a relationship between serum Ox-LDL concentrations and serum TG concentrations in our STZ-diabetic rats. 18 In patients with type-2 diabetes, hyperglycaemia enhances the oxidative stress, further modifying LDL into Ox-LDL, which is likely occurring in our type 1 hyperglycaemic STZ diabetic rats. This association is seen even in healthy volunteers where transiently increased plasma glucose levels correlate with higher oxidation of LDL. 20 Moreover, an inverse relationship has been observed between LDL sizes and circulating Ox-LDL in type 2 diabetic patients. 21 In fact, the formation of small, dense LDL particles is mostly observed in hypertriglyceridaemic states. Ox-LDL, so caution needs to be applied when interpreting results and comparing across studies. 24 Our dyslipidaemic STZ-diabetic rats showed endothelial dysfunction through impaired cholinergic-induced endothelium-dependent aortic vasodilation ( Figure 3 ) consistent with Fukao et al. 25 Increased circulating Ox-LDL in our STZ-diabetic rats may directly damage arteries, possibly via the Ox LDL receptor, LOX-1, which is upregulated in the vascular endothelium of diabetic animals, leading to foam cell formation and plaque development, as a causal relationship between Ox-LDL and atherosclerosis is well established. 26 Moreover, an increased Ox-LDL/apoB ratio has been associated with macrovascular disease and peripheral neuropathy in Japanese patients with type 2 diabetes. 18 Oxidized LDL molecules are recognized by the CD36 endothelial scavenger receptor that facilitates the uptake and the endocytosis of Ox-LDL. 27 Oxidized LDL molecules are cholesterol acceptors that compete with caveolae to deplete the caveolae from cholesterol and hence cause caveolae disruption displacing eNOS. 28 Such caveolae disruption would inhibit eNOS attachment to CAV-1 and subsequent eNOS activation, 28 therefore yielding endothelial dysfunction, as observed seen in our STZ diabetic rats ( Figure 3 ) and depicted in Figure 6 . Furthermore, the elevated serum Ox-LDL in our STZ-diabetic rats may directly inhibit eNOS attachment to CAV-1 and hence reduce the eNOS coupling with CAV-1 that culminates in compromised eNOS activity and subsequent NO release and vasodilation. 29 In support of this hypothesis, our immunocytochemistry studies Figure 6 ). Interestingly, the 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors, simvastatin and lovastatin, protect eNOS activity from Ox-LDL-induced downregulation. 31 High-density lipoprotein binds mainly on scavenger receptor class B isoform I (SR-BI) where it delivers the circulating cholesterol to the caveolae maintaining the caveolae integrity and enhancing eNOS activity, which may support a benefit for increasing the HDL/ cholesterol ratio. 32 The mechanism of CAV-1 and eNOS downregulation and reduced eNOS activity in diabetic aortic ECs needs further investigation.
| CONCLUSION
In summary, STZ-diabetic rats showed significant endothelial dysfunction demonstrated by impaired CC-induced vasodilation. Such endothelial dysfunction was accompanied by eNOS and CAV-1 downregulation in STZ-diabetic aortic primary ECs. Streptozotocindiabetic rats showed a significant increase in serum Ox-LDL level, which may contribute to the oxidative and carbonyl stress associated with diabetic eNOS and CAV-1 endothelial dysfunction.
